Modern Cardiac Surgical Outcomes in Nonagenarians: A Multicentre Retrospective Observational Study

Laurence Weinberg¹,²*, Dominic Walpole¹, Dong Kyu Lee³, Michael D’Silva¹, Jian Wen Chan¹, Lachlan Fraser Miles¹,², Bradly Carp¹, Adam Wells⁴, Tuck Seng Ngun¹, Siven Seevanayagam⁵, George Matalanis⁵, Ziauddin Ansari⁶, Rinaldo Bellomo²,⁷ and MichaelYii⁴

¹ Department of Anaesthesia, Austin Health, Melbourne, VIC, Australia, ² Department of Critical Care, The University of Melbourne, Melbourne, VIC, Australia, ³ Department of Anesthesiology and Pain Medicine, Dongguk University Ilsan Hospital, Goyang, South Korea, ⁴ Department of Cardiac Surgery, Epworth Eastern Hospital, Melbourne, VIC, Australia, ⁵ Department of Cardiac Surgery, Austin Health, Melbourne, VIC, Australia, ⁶ Department of Intensive Care, Epworth Eastern Hospital, Melbourne, VIC, Australia, ⁷ Department of Intensive Care, Austin Health, Melbourne, VIC, Australia

Background: There have been multiple recent advancements in the selection, optimisation and management of patients undergoing cardiac surgery. However, there is limited data regarding the outcomes in nonagenarians, despite this cohort being increasingly referred for these interventions. The objective of this study was to describe the patient characteristics, management and outcomes of a cohort of nonagenarians undergoing cardiac surgery receiving contemporary peri-operative care.

Methods: After receiving ethics approval, we conducted a retrospective observational study of nonagenarians who had undergone cardiac surgery requiring a classic median sternotomy. All operative indications were included. We excluded patients who underwent transcatheter aortic valve implantation (TAVI), and surgery on the thoracic aorta via an endovascular approach (TEVAR). Patients undergoing TEVAR often have the procedure done under sedation and regional blocks with local anesthetic solution. There is no open incision and these patients do not require cardiopulmonary bypass. We also excluded patients undergoing minimally invasive mitral valve surgery via a videoscope assisted approach. These patients do not have a median sternotomy, have the procedure done via erector spinae block, and often are extubated on table. Data were collected from four hospitals in Victoria, Australia, over an 8-year period (January 2012–December 2019). The primary objective was to assess 6-month mortality in nonagenarian patients undergoing cardiac surgery and to provide a detailed overview of postoperative complications. We hypothesized that cardiac surgery in nonagenarian patients would be associated with a 6-month postoperative mortality <10%. As a secondary outcome, we hypothesized that significant postoperative complications (i.e., Clavien Dindo Grade IIIb or greater) would occur in > 30% of patients.

Results: A total of 12,358 adult cardiac surgery patients underwent surgery during the study period, of whom 18 nonagenarians (0.15%) fulfilled inclusion criteria. The median (IQR) [min-max] age was 91.0 years (90.0:91.8) [90–94] and the median body mass index was 25.0 (kg/m²) (22.3:27.0). Comorbidities, polypharmacy, and frailty were

OPEN ACCESS
common. The median predicted mortality as per EuroSCORE-II was 6.1% (4.1:14.5). There were no cases of intra-operative, in-hospital, or 6-month mortality. One (5.6%) patient experienced two Grade IIIa complications. Three (16.7%) patients experienced Grade IIIb complications. Three (16.7%) patients had an unplanned hospital readmission within 30 days of discharge. The median value for postoperative length of stay was 11.6 days (9.8:17.6). One patient was discharged home and all others were discharged to an inpatient rehabilitation facility.

**Conclusion:** In this selected, contemporary cohort of nonagenarian patients undergoing cardiac surgery, postoperative 6-month mortality was zero. These findings support carefully selected nonagenarian patients being offered cardiac surgery (Trials Registry: https://www.anzctr.org.au/ACTRN12622000058774.aspx).

**Keywords:** cardiac surgery, anesthesia, nonagenarians, outcomes, complications, mortality, acute kidney injury, delirium

## INTRODUCTION

Very elderly patients undergoing cardiac surgery are vulnerable (1). However, as life expectancy continues to rise in resource rich countries, the global population of nonagenarians is expected to increase from 16.3 million in 2015 to an estimated 30.9 million in 2030. (2) Additionally, the proportion of the over-75 population being offered, and accepting surgical intervention is increasing (3, 4). Accordingly, the number of nonagenarians presenting for surgery is also expected to increase. These demographic changes present clinical challenges.

Advanced age increases the risks of surgery, with a linear association between advanced age and worse postoperative outcomes (1). Advanced age is associated with physiological derangements and a greater burden of comorbidity. The estimated postoperative survival rates after surgery for nonagenarians at one, 3–5 years are 59.6, 35.8 and 24.1%, respectively (5, 6). Such studies, however, have examined individuals undergoing non-cardiac surgery, (7, 8) and have not provided granular insights into the anesthetic and peri-operative course of cardiac surgical patients. This is a significant knowledge gap, and there is little evidence to guide and inform the patient selection and peri-operative care of nonagenarians undergoing cardiac surgery.

Accordingly, we conducted a retrospective observational study to describe the peri-operative care and postoperative outcomes of nonagenarians undergoing cardiac surgery.

## MATERIALS AND METHODS

### Study Objectives

The primary objective of this study was to determine the 6-month mortality in nonagenarian patients undergoing cardiac surgery, and to provide a detailed overview of postoperative complications.

The secondary aims were to describe peri-operative management, including patient characteristics, comorbidity burden, indications for surgery, anesthesia medications, use of fluids, vasoactive drugs and inotropes, and postoperative course.

We hypothesized that cardiac surgery in nonagenarian patients would be associated with postoperative mortality within 6 months of surgery of <10%. Secondarily, we hypothesized that significant postoperative complications--defined as the development of a Clavien Dindo Grade IIIb or greater complications--would occur in >30% of patients.

### Data Sources and Processing

We conducted a multicentre retrospective study of nonagenarians who had undergone cardiac surgery requiring a classic median sternotomy. We excluded patients undergoing minimally invasive mitral valve or aortic surgery. These patients are younger, and this procedure undertaken via a thoracoscopic approach, often with a with erector spinae block. Accordingly, they do not have a midline sternotomy incision. We excluded patients undergoing surgery on the thoracic aorta via an endovascular approach (TEVAR) and patients undergoing transfemoral aortic valve replacements (TAVR). These patients have the procedure under sedation and regional blocks with local anesthetic solution. There is no open incision and these patients do not require cardiopulmonary bypass.

Data were collected from three hospitals in Melbourne, Victoria, Australia, over an 8-year period from 1 January 2012 to 31 December 2019. These hospitals were Austin Hospital, Warringal Hospital and Epworth Eastern Hospital. All hospitals are university teaching institutions, and all procedures were undertaken by a dedicated multidisciplinary team of consultant cardiac anesthetists, surgeons, and intensivists, who work across all three institutions. The study was approved by the Austin Health Human Research Ethics Committee (HREC 21/30).

Written informed consent was waived as only de-identified data was collected. The study was registered with the Australian New Zealand Clinical Trials Registry (https://www.anzctr.org.au/ACTRN12622000058774.aspx). Data were collected from a prospectively managed, electronic surgical database (Cerner Millenium®, Missouri, USA) and from the scanned medical records of anesthesia charts. A team of two experienced clinicians reviewed and crosschecked the data. Two other clinicians checked each record independently.
We included patients’ preoperative characteristics, perioperative laboratory values, surgical data, and intensive care unit (ICU) admission data. Socio-economic status and frailty were also assessed and recorded. Risk factors, preoperative medications, and comorbidities relevant to suitability for surgery were recorded, and operative risk calculated. Key features of the preoperative paradigm, including results of recent blood testing, transthoracic echocardiography and coronary angiography, were collated if available. The time from admission to surgery was also recorded. An analysis of postoperative complications, in-hospital mortality and readmissions was performed. Discharge destination was obtained, as was any record of follow-up and the time from surgery to the last follow-up encounter.

**Definitions**

‘Rural’ residence was defined as Modified Monash Model Category 2 or higher (9). Socio-economic status was assessed based on the national percentile rank of patients’ residential postcode in the Australian Bureau of Statistics Socio-economic Indexes for Areas Index of Relative Socio-economic Advantage and Disadvantage, with higher rankings indicating greater advantage and lesser disadvantage on specific socio-economic measures relative to other areas (10). Frailty was defined as a score of 5 or higher on the Canadian Study on Health and Aging Clinical Frailty Scale (11).

Previous myocardial infarction was defined as “recent” or “remote” if it occurred within or more than 90 days, respectively, of the index operation (12).

Heart failure was characterized using the Heart Foundation of Australia guidelines (13). Extracardiac arteriopathy was defined as one or more of the following: claudication; carotid occlusion or > 50% stenosis; previous amputation for arterial disease; and previous or planned intervention on abdominal aorta, limb arteries or carotids (12). Chronic kidney disease was defined and staged according to the glomerular filtration rate criteria in the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guideline for chronic kidney disease (14). Anemia was defined according to World Health Organization criteria (15). The overall burden of comorbidity was quantified using the Charlson Comorbidity Index (16).

The total number of medications included prescribed, over-the-counter and as-required medications administered by oral, inhaled, rectal, vaginal, intramuscular, subcutaneous or intravenous routes. Topical medications including creams, lotions and ointments for wound care and eye drops were not recorded. Polypharmacy was defined as five or more medications (17).

The urgency of surgery was considered ‘elective’ for patients admitted routinely for the operation, ‘urgent’ for those not electively admitted for the operation but requiring surgery during the current admission and ‘emergent’ for those requiring surgery before the beginning of the next working day after the decision to operate. After-hours surgery was defined as surgery commencing or finishing between 1800 and 0800 h.

The American Society of Anesthesiologists (ASA) physical status classification for patients was based on the treating anesthetists’ assessment immediately prior to surgery. “Critical preoperative state” denoted patients having one or more of the following in the same hospital admission as the operation: ventricular fibrillation, ventricular tachycardia or aborted sudden death; cardiac massage; ventilation before arrival to the operating room; inotropes; intra-aortic balloon pump or ventilator-assist device before arrival to the operating room; or acute renal failure (anuria or oliguria < 10 mL/hr) (12). The predicted operative risk of in-hospital mortality was calculated for each patient using the EuroSCORE II risk model (12). The estimated risk of requiring renal replacement therapy (RRT) postoperatively was calculated using the Cleveland Clinic Score (18).

A complication was defined as any deviation from the normal postoperative course and graded using the Clavien–Dindo classification system (19). “Return to theatre” was defined as surgery within 30 days of the index operation due to a related complication, and ‘readmission’ was defined as an unplanned admission within 30 days of discharge. Acute kidney injury (AKI) was defined and staged according to the KDIGO 2012 guidelines for AKI (14).

Time to surgery was defined as the time from admission to the start of anesthesia. Duration of mechanical ventilation was defined as the time from the end of surgery to tracheal extubation. Time to first oral intake and time to first mobilization to chair were measured from the end of surgery. The postoperative and total lengths of stay were defined as the time from surgery to discharge and the time from admission to discharge, respectively.

**Statistics**

Statistical analysis was performed using IBM SPSS Statistics for Windows, version 23 (IBM Corp., 2015, Armonk, NY, USA) and Stata/SE 13.0 for Windows (StataCorp LP, Texas, USA, 2013). Data were de-identified, variable names were encrypted, and all data were coded with numerical values to blind the collected variables’ characteristics to the statistician. The descriptive statistics presented below are shown as either median (with interquartile range; minimum–maximum in parentheses) or number (and percentage in parentheses). Only non-zero data points were included in the calculation of descriptive statistics for numerical variables (e.g., drug doses and periods). The study is reported following The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (20).

**RESULTS**

**Preoperative Paradigm**

Over the study period 12,391 adult patients were considered for open cardiac surgery via a median sternotomy approach, of whom 49 (0.39%) were nonagenarians. There were no nonagenarians who underwent minimally invasive aortic or mitral surgery, or TEVAR. Thirty-three patients were considered for TAVR, of which 27 underwent this procedure for severe symptomatic aortic stenosis. Six patients with severe aortic stenosis were deemed at prohibitive risk for both SAVR and TAVR and were accordingly managed conservatively. Of the remaining 2,358 patients who underwent open cardiac surgery, 18 (0.15%) nonagenarians fulfilled the inclusion
| Variable | Open cardiac surgery (N = 18) | Transcatheter aortic valve replacement (N = 27) |
|----------|-----------------------------|-----------------------------------------------|
| Surgical procedure |                             |                                               |
| Aortic valve replacement (isolated) | 2 (11%) | 27 (100%) |
| Aortic valve replacement, ascending aorta replacement | 2 (11%) | N/A |
| Aortic valve and mitral replacement, tricuspid valve repair, left atrial Maze procedure, ligation of left atrial appendage | 1 (6%) | N/A |
| Aortic valve replacement, CABG | 2 (11%) | N/A |
| Aortic valve replacement, CABG, ligation of left atrial appendage | 2 (11%) | N/A |
| Aortic valve replacement, CABG, tricuspid valve repair, left ventricular epicardial pacing lead | 1 (6%) | N/A |
| CABG (isolated) | 4 (22%) | N/A |
| CABG, ligation left atrial appendage | 1 (6%) | N/A |
| CABG, ligation left atrial appendage, left atrial Maze procedure | 1 (6%) | N/A |
| CABG, mitral valve replacement, ligation of left atrial appendage, closure of patent foramen ovale | 1 (6%) | N/A |
| Mitral valve replacement, tricuspid valve repair, ligation of left atrial appendage, closure of patent foramen ovale | 1 (6%) | N/A |
| Patient characteristics |                             |                                               |
| Age | 91.0 (90.0:91.8), [90–94] | 92.0 (90.0:93), [90–98] |
| Female | 4 (22%) | 11 (40.7%) |
| Male | 14 (78%) | 16 (59.3%) |
| Body mass index (kg/m²) | 25.0 (22.3:27.0), [18–30] | 24.0 (22.1:25.0), [17–31] |
| Residential status |                             |                                               |
| Home | 17 (94%) | 26 (96.3%) |
| Residential care facility | 1 (6%) | 1 (0.7%) |
| Rurality and socio-economic status |                             |                                               |
| Rural residence | 6 (33%) | 4 (9.4%) |
| MMM category | 1.0 (1.0:2.0), [1–5] | 1.0 (1.0:2.0), [1–4] |
| SEIFA (IRSAD) percentile | 78 (56:89), [21–94] | 77 (55:88), [27–93] |
| Frailty |                             |                                               |
| Mild or greater | 10 (56%) | 7 (25.6%) |
| CSHA frailty grade | 5.0 (4.0:5.0), [4–6] | 3.0 (2.0:4.0), [3–4] |
| Comorbidities |                             |                                               |
| Hypertension | 12 (67%) | 13 (48.1%) |
| Atrial fibrillation | 5 (28%) | 1 (3.7%) |
| Recent myocardial infarction | 4 (22%) | 0 |
| History of myocardial infarction | 2 (11%) | 2 (7.4%) |
| Previous PCI | 5 (28%) | 1 (4.2%) |
| Previous cardiac surgery | 0 (0%) | 0 |
| Permanent pacemaker | 3 (17%) | 1 (3.7%) |
| Heart failure | 12 (67%) | 4 (29.6%) |
| NYHA functional class |                             |                                               |
| 1 | 0 (0%) | 5 (20.9%) |
| 2 | 6 (33%) | 13 (18.5%) |
| 3 | 11 (61%) | 6 (22.2%) |
| 4 | 1 (6%) | 0 |
| Stroke/TIA | 2 (11%) | 2 (7.4%) |
| Current smoker | 0 (0%) | 0 |
| Past smoker | 7 (39%) | 4 (29.6%) |
| Extracardiac arteriopathy | 3 (17%) | 0 |
| Chronic lung disease | 4 (22%) | 0 |
| Diabetes mellitus | 4 (22%) | 2 (7.4%) |
| Chronic kidney disease | 11 (61%) | 8 (29.6%) |

(Continued)
TABLE 1 | Continued

| Variable                          | Open cardiac surgery \((N = 18)\) | Transcatheter aortic valve replacement \((N = 27)\) |
|----------------------------------|----------------------------------|----------------------------------|
| Chronic kidney disease (stage)   |                                  |                                  |
| 1                                | 0 (0%)                           | 5 (18.5%)                        |
| 2                                | 0 (0%)                           | 3 (11.2%)                        |
| 3a                               | 4 (22%)                          | 0                                |
| 3b                               | 5 (28%)                          | 0                                |
| 4                                | 2 (11%)                          | 0                                |
| 5                                | 0 (0%)                           | 0                                |
| Anemia                           | 11 (61%)                         | 9 (33.3%)                        |
| Neurological/musculoskeletal dysfunction | 3 (17%)               | 0                                |
| Chronic liver disease            | 0 (0%)                           | 0                                |
| Dementia                         | 1 (6%)                           | 0                                |
| Localised solid malignancy       | 2 (11%)                          | 0                                |
| Leukemia                         | 2 (11%)                          | 0                                |
| Charlson comorbidity Index       |                                  |                                  |
| Score                            | 6.0 (5.0:6.8), [4–9]             | 6.0 (5.0:6.2), [5–10]            |

Binary variables are presented as n (% patients), and numerical variables are presented as Mdn [interquartile range], range (minimum–maximum). MMM, modified monash model; SEIFA (IRSAD), socio-economic indexes for areas (index of relative socio-economic advantage and disadvantage); CSHA, Canadian study of health and ageing; PCI, percutaneous coronary intervention; NYHA, New York heart association; TIA, transient ischemic attack; CCI, charlson comorbidity index.

criteria. Two nonagenarians underwent isolated surgical aortic valve replacement (SAVR). Both these patients had critical symptomatic aortic stenosis and transfemoral access, valve and aortic morphology were unfavorable for TAVR. Of the remaining patients who underwent open cardiac surgery, 12 patients underwent coronary artery bypass grafting (CABG, of which four had isolated CABG, two had CABG plus left atrial appendage ligation and or a MAZE procedure, and six patients underwent CABG plus single or double valve replacement. One patient had a double valve replacement, and one patient had a triple valve replacement.

The demographics, socio-economic status and comorbidities of the 18 patients who underwent open cardiac surgery are summarized in Table 1. The median (IQR) \([\text{min-max}]\) age was 91 years \((90.0:91.8)\) \([90–94]\) and the median (IQR) body mass index was 25.0 kg\(\text{/m}^2\) \((22.3:27.0)\). Most were men. Most patients resided in areas ranked above the 50th socioeconomic percentile relative to the rest of the nation. Approximately half were frail. Baseline characteristics of nonagenarians who underwent TAVR in our institution are also present in Table 1.

In nonagenarians undergoing open cardiac surgery, hypertension, heart failure, chronic kidney disease and anaemia were the most common comorbidities. Previous myocardial infarction and percutaneous coronary intervention were also frequent. Only one patient had a diagnosis of mild dementia. A multidisciplinary team comprising a cardiac surgeon, cardiologist, anaesthetist and geriatrician assessed all patients preoperatively and sought to optimise their preoperative condition.

The participants’ preoperative medications are summarised in Table 2. Polypharmacy was common. Preoperative hematological and biochemical results, echocardiography and coronary angiography findings are summarised in Table 3. The median haemoglobin was slightly below normal. The baseline estimated glomerular filtration rate was \(<60 \text{ mL/min}/1.73 \text{ m}^2\) for more than half of patients, with two \((11\%)\) patients recording values \(<30 \text{ mL/min}/1.73 \text{ m}^2\). Significant valve disease was reported in 11 \((61\%)\) patients, predominantly severe aortic stenosis, followed by severe mitral regurgitation. Regional wall motion abnormalities were recorded in one-third of patients.

Preoperative Operative Risk

Details of the type of surgery performed, participants’ preoperative status and predicted operative risk are presented in Table 4. Approximately half of the surgeries were elective, one-third were urgent, and two were emergent. Almost half of surgeries occurred out of hours. Preoperatively, almost all patients were assigned an ASA physical status class of 4. One patient was in a critical preoperative state, requiring mechanical ventilation and a noradrenaline infusion during transport to the operating theatre. The median EuroSCORE II predicted in-hospital mortality was 6.1% \((4.1:14.5)\) \([1.8–34.3]\).

Intraoperative and Postoperative Management

Key features of postoperative management are summarised in Tables 5, 6. All patients had an arterial line inserted prior to induction of anesthesia. Vascular access for all patients included a pulmonary artery catheter, central venous catheter, and a large-gauge peripheral cannula. Vascular access lines were inserted prior to induction in more than half of patients. Prophylactic antibiotics were administered to all patients prior to skin incision. All operations were conducted on cardiopulmonary bypass with cardioplegia administered and patients heparinised then reversed...
TABLE 2 | Preoperative medications of nonagenarians undergoing open cardiac surgery via a sternotomy.

| Medication                        | Open cardiac surgery (N = 18) |
|----------------------------------|-------------------------------|
| Aspirin                          | 13 (72%)                      |
| Beta blocker                     | 11 (61%)                      |
| ACEi/ARB                         | 8 (44%)                       |
| Statin                           | 8 (44%)                       |
| Nitrites/antianginals            | 7 (39%)                       |
| Frusemide                        | 7 (39%)                       |
| Dihydropyridine CCB             | 6 (33%)                       |
| P2Y12 inhibitor (clopidogrel)    | 6 (33%)                       |
| Proton pump inhibitor            | 5 (28%)                       |
| Inhaled bronchodilators or steroids | 4 (22%)                     |
| Other antiarrhythmic             | 3 (17%)                       |
| Oral diabetes medications       | 3 (17%)                       |
| Direct-acting oral anticoagulant | 2 (11%)                      |
| Insulin                          | 2 (11%)                       |
| Fibrate                          | 1 (6%)                        |
| Warfarin                         | 1 (6%)                        |
| Polypharmacy                     | 13 (72%)                      |
| Total number of medications     | 6.5 (4.3:8.8), [0–16]        |

Binary variables are presented as n (%) patients, and numerical variables are presented as Mdn [interquartile range], range (minimum–maximum). ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.

Complications, Inpatient Mortality, Length of Stay and Follow-Up

A summary of postoperative complications, lengths of stay, discharge destinations and follow-up are provided in Table 7. For nonagenarians undergoing open cardiac surgery, all patients except one suffered a postoperative complication. The most common complication was AKI (Stage 1 in five patients, Stage 2 in six patients and Stage 3 in two patients). New atrial fibrillation and/or flutter and delirium were also common complications. No patients required reintubation, tracheostomy, intra-aortic balloon counterpulsation or renal replacement therapy in the postoperative period. Postoperatively, most patients were treated with diuretics (typically furosemide) and antiarrhythmics (generally amiodarone and/or metoprolol).

Overall, 14 (78%) patients suffered at least one Grade I complication, and 10 (56%) patients suffered at least one Grade II complication. One (6%) patient experienced two Grade IIIa complications: pneumothorax and pleural effusion—both requiring separate radiologically guided insertion of an intercostal catheter. Three (17%) patients experienced Grade IIIb complications: two underwent insertion of a permanent pacemaker, and one underwent gastroscopy and hemostatic with protamine. Transoesophageal echocardiography was performed immediately before and after cardiopulmonary bypass in all patients. Cardiac output was monitored intraoperatively by thermodilution for all patients.

TABLE 3 | Preoperative variables of nonagenarians undergoing open cardiac surgery.

| Variable                                      | Open cardiac surgery (N = 18) |
|-----------------------------------------------|-------------------------------|
| Preoperative blood testing                    |                               |
| Hemoglobin (g/L)                              | 123 (114:133), [98–140]       |
| Platelets                                     | 235 (206:292), [165–372]      |
| Albumin (g/L)                                 | 36 (34:37), [29–40]           |
| International normalised ratio               | 1.1 (1.1:1.2), [1.0–1.4]      |
| Ferritin (mmol/L)                             | 109 (69:150), [41–219]        |
| Troponin (mmol/L)                             | 853 (43:869), [15–2,445]      |
| B-type natriuretic peptide (pg/mL)           | 126 (111:137), [27–499]       |
| Estimated glomerular filtration rate (mL/min/1.73 m²) |                               |
| ≥90                                           | 1 (6%)                        |
| 60–89                                         | 7 (39%)                       |
| 45–59                                         | 4 (22%)                       |
| 30–44                                         | 4 (22%)                       |
| 15–29                                         | 2 (11%)                       |
| <15                                           | 0 (0%)                        |
| Preoperative transthoracic echocardiography  |                               |
| Transthoracic echocardiogram available        | 16 (89%)                      |
| Left ventricular ejection fraction (%)        | 9 (56%)                       |
| ≤50                                           |                               |
| 1–50                                          | 5 (22%)                       |
| 21–30                                         | 1 (6%)                        |
| ≤20                                           | 1 (6%)                        |
| Left ventricular hypertrophy                  | 10 (56%)                      |
| Left ventricle dilatation                     | 1 (6%)                        |
| Left atrium dilatation                        | 14 (78%)                      |
| Right ventricle systolic dysfunction          | 2 (11%)                       |
| Estimated pulmonary artery pressure (mmHg)    |                               |
| ≤30                                           | 7 (39%)                       |
| 31–54                                         | 8 (44%)                       |
| ≥55                                           | 1 (6%)                        |
| Valve function                                |                               |
| Significant valve disease                     | 11 (61%)                      |
| Aortic stenosis                               |                               |
| Mild                                          | 2 (11%)                       |
| Moderate                                      | 1 (6%)                        |
| Severe                                        | 8 (44%)                       |
| Aortic regurgitation                          |                               |
| Mild                                          | 4 (22%)                       |
| Moderate                                      | 4 (22%)                       |
| Severe                                        | 0 (0%)                        |
| Mitral regurgitation                          |                               |
| Mild                                          | 6 (33%)                       |
| Moderate                                      | 1 (6%)                        |
| Severe                                        | 3 (17%)                       |
| Tricuspid regurgitation                       |                               |
| Mild                                          | 5 (28%)                       |
| Moderate                                      | 3 (17%)                       |
| Severe                                        | 1 (6%)                        |
| Regional wall motion abnormality              | 6 (33%)                       |
| Preoperative coronary angiography             |                               |
| Coronary angiogram available                 | 14 (78%)                      |

(Continued)
clipping for gastric haemorrhage. There were no cases of intraoperative or in-hospital mortality.

Three (17%) patients had an unplanned hospital readmission within 30 days of discharge: one with AKI and *Enterococcus faecalis* bacteraemia secondary to a urinary tract infection, one with an infective exacerbation of chronic obstructive pulmonary disease and one with shingles and a pleural effusion. All three patients had an additional diagnosis of congestive cardiac failure.

The median values for the postoperative length of stay and total length of stay were 11.6 and 15.9 days, respectively. One (6%) patient was discharged home, and all others were discharged to an inpatient rehabilitation facility. At 6 months after surgery, all patients were alive. Ten (56%) patients had a record of follow-up 6 months after discharge. The median (IQR) time to the last documented follow-up encounter was 11.3 months (60:69.4). For comparison, a summary of postoperative complications, lengths of stay, discharge destinations and follow-up for nonagenarians undergoing TAVR are summarised in Table 7.

### DISCUSSION

#### Key Findings

In this multicentre retrospective contemporary cohort study of 18 nonagenarian patients undergoing cardiac surgery requiring cardiopulmonary bypass, we tested the primary hypothesis that mortality at 6 months would be <10% and the secondary hypothesis that serious complications would occur in >30% of patients. In keeping with our hypothesis, and despite a high median preoperative EuroSCOREs, most complications were mild to moderate, and the in-hospital and six-month mortality was zero. No patients developed organ failure, and no cerebrovascular events were recorded. Finally, while there was a loss of long-term follow-up data after 6 months, for those followed up, all were still alive at 11 months after surgery.

#### Relationship to the Literature

Granular information about polypharmacy, anaesthesia medications, use of fluids, vasoactive drugs and inotropes and detailed description and grading of complications in nonagenarian patients undergoing cardiac surgery is lacking. In total, 21 studies have reported on postoperative outcomes of nonagenarians undergoing cardiac surgery (see Figure 1) (21–42). Most of these studies included <50 patients. In contrast to our outcomes, in-hospital or 30-day mortality was between 6 and 23%. Only two studies were published in the last 2 years, (28, 36) and only reported outcomes in nonagenarians undergoing surgical aortic valve replacement. Both these series, with a combined total of 1,992 patients, interrogated the same database (National Inpatient Sample database, United States) over overlapping time periods. Inpatient mortality was 6% and longer-term outcomes were not reported.

Interestingly in our series, only two patients with severe symptomatic aortic stenosis underwent isolated SAVR. This precludes direct comparisons with nonagenarians who underwent TAVR patients. In both nonagenarians who underwent SAVR, aortic stenosis was critical with severe symptoms. In both patients transfemoral access and valve and aortic morphology were unfavourable for TAVR. Over the study period our practices in the selection of nonagenarian patients for TAVR were informed by several randomized clinical trials (RCTs) comparing SAVR and TAVR, as well as large-scale...
TABLE 5 | Intraoperative variable of nonagenarians undergoing open cardiac surgery.

| Variable | Open cardiac surgery (N = 18) |
|----------|--------------------------------|
| **Duration** | |  |
| Total surgery time (minutes) | 270 (229:341), [180–450] |
| Cardiopulmonary bypass time (minutes) | 121 (95:158), [57–251] |
| Cross-clamp time (minutes) | 95 (74:143), [48–231] |
| **Monitoring** | |  |
| Lowest pH on bypass | 7.33 (7.30:7.38), [7.27–7.47] |
| Lowest temperature on bypass (°C) | 33.5 (33.4:34.0), [28.1–34.5] |
| **Anaesthesia** | |  |
| Premedication | 17 (94%) |
| Induction agent | |  |
| Fentanyl | 12 (67%) |
| Propofol | 8 (11%) |
| Alfentanil | 4 (22%) |
| Remifentanil | 2 (11%) |
| Ketamine | 1 (6%) |
| Volatile anesthesia only | |  |
| Sevoflurane | 10 (56%) |
| Intravenous anesthesia only | |  |
| Propofol | 1 (6%) |
| Remifentanil | 1 (6%) |
| Remifentanil + propofol + ketamine | 1 (6%) |
| Volatile and intravenous anaesthesia combined | |  |
| Propofol + sevoflurane | 4 (22%) |
| Propofol + isoflurane | 1 (6%) |
| Muscle relaxant | |  |
| Rocuronium | No. of patients (%) | 14 (78%) |
| Total dose (mg) | 100 (100:100), [50–150] |
| Pancuronium | No. of patients (%) | 2 (11%) |
| Total dose (mg) | 6.0, 12.0 |
| Cisatracurium | No. of patients (%) | 2 (11%) |
| Total dose (mg) | 10.0, 40.0 |
| **Vasoactive medications** | |  |
| Any vasoactive | 15 (83%) |
| Metaraminol | No. of patients (%) | 8 (44%) |
| Total dose (mg) | 1.0 [0.5–1.1], [0.5–3.0] |
| Noradrenaline | No. of patients (%) | 5 (28%) |
| Total dose (mg) | 0.1 [0.1–1.2], [0.1–2.1] |
| Milrinone | No. of patients (%) | 3 (17%) |
| Total dose (mg) | 2.0, 2.7, 3.0 |
| Ephedrine | No. of patients (%) | 2 (11%) |
| Total dose (mg) | 9.0, 24.0 |
| Adrenaline | No. of patients (%) | 1 (6%) |
| Total dose (mcg) | 45.0 |
| Atropine | No. of patients (%) | 1 (6%) |
| Total dose (mg) | 0.3 |
| **Opioids** | |  |
| Any opioid | 18 (100%) |
| Intravenous morphine equianalgesic dose (mg) | 33 (28:54), [0.1–83] |
| Morphine | No. of patients (%) | 6 (33%) |
| Total dose (mg) | 10 (10:10), [5–10] |
| Fentanyl | No. of patients (%) | 12 (67%) |

(Continued)
TABLE 5 | Continued

| Variable | Open cardiac surgery (N = 18) |
|----------|-------------------------------|
| **Variable** | **Total dose (mcg)** | **No. of patients (%)** | **Remifentanil** | **Total dose (mcg)** | **Total dose (mg)** |
| Alfentanil | 625 (500:1,000), [350–1,250] | 4 (22%) | 20 (17:20), [7–20] | 2 (11%) |
| **Intravenous fluids** | **Total dose (mcg)** | **No. of patients (%)** | **Total dose (L)** | **No. of patients (%)** | **Total volume (L)** |
| Any intravenous fluids | Not applicable | 14 (78%) | 1.0 (1.0:1.7), [0.3–3.3] |
| Crystalloids (CSL) | Not applicable | 10 (56%) | 0.5 (0.5:0.5), [0.2–0.5] |
| Colloids (4% albumen) | Not applicable | 10 (56%) |
| **Blood products** | **Unprocessed residual pump blood** | **No. of patients (%)** | **Total volume (mL)** |
| No. of patients (%) | 18 (100%) | 566 (467:677), [400–720] |
| Any blood products | 11 (61%) |
| Red blood cells | 8 (44%) | 2.0 (1.8:2.3), [1–7] |
| Platelets | 6 (33%) | 2.0 (1.3:2.0), [1–3] |
| Cryoprecipitate | 5 (28%) | 5.0 (5.0:6.0), [5–10] |
| Fresh frozen plasma | 2 (11%) | 2, 3 |
| Prothrombinex | 5 (28%) | 1,500 (1,000:2,000), [1,000–3,000] |
| **Other therapies** | **Antifibrinolytic** | 17 (94%) |
| Insulin | 3 (17%) |
| Diuretic | 4 (22%) |
| Desmopressin | 1 (6%) |

Binary variables are presented as n (%) patients. Except where noted, numerical variables are presented as Mdn [interquartile range], range (minimum–maximum) and only include non-zero results. Where there are fewer than four data points for a numerical variable, individual patient results are listed. CSL, compound sodium lactate.

registry data (43–47). Our indications for TAVR also expanded to include lower risk populations (45–50).

We favour TAVR in patients that are at increased surgical risk i.e., Society of Thoracic Surgeons (STS) or EuroSCORE II ≥4%, or other risk factors not included in these scores, such as severe frailty, porcelain aorta, sequelae of chest radiation, and presence of intact coronary artery bypass grafts when sternotomy is performed. We also favour TAVR in patients >75 years suitable for transfemoral access, unless there are anatomical or technical aspects that preclude the procedure i.e., unfavourable vascular access, short distance between the coronary ostia and aortic valve annulus, size of aortic annulus out of range for TAVR, and preclusive valve morphology (degree of calcification or calcification pattern unsuitable for TAVR). In patients with cardiac conditions that require consideration for concomitant surgical intervention (~50% of patients in our cohort), or patients at low surgical risk (STS or EuroSCORE II <4% and no other risk factors not included in these scores, as stated above), SAVR remains our preferred option.

Over our study period patient selection was also informed by three other clinical trials comparing TAVR and SAVR. In the PARTNER-II, SURTAVI and NOTION trials, (46–48) robust randomised data demonstrated the equivalence, and even net superiority of TAVR in intermediate-risk and lower-risk patients. Therefore, in our institution, there was a further expansion of TAVR indications to encompass lower-risk patients, as outlined in the updated 2017 ESC/EACTS guidelines on the management of valvular heart disease (51). Finally, our practices are changing given the most recent evidence that among patients aged 70 years or older with severe, symptomatic aortic stenosis and moderately increased operative risk, TAVR was non-inferior to surgery with respect to all-cause mortality at 1 year (52).
TABLE 6 | Postoperative management of nonagenarians undergoing open cardiac surgery.

| Variable | Open cardiac surgery (N = 18) |
|----------|-----------------------------|
| **Recovery parameters** | |
| Duration of mechanical ventilation (hours) | 10.0 (8.1:13.2), [3.5–33.3] |
| Time to first oral intake (hours) | 15.4 (14.5:20.9), [9.2–40.6] |
| Time to first mobilize to chair (hours) | 27.0 (18.1:41.5), [13.5–61.5] |
| Time to removal of drain tubes (days) | 1.9 (1.7:2.1), [1.0–4.7] |
| Duration of epicardial pacing time (days) | 1.7 (0.5:3.3), [0.3–6.2] |
| Duration of inotrope or vasopressor support (days) | 2.1 (1.8:3.5), [0.4–6.7] |
| Length of stay in intensive care unit (days) | 2.6 (2.1:4.6), [0.9–7.0] |
| **Other parameters** | |
| Lowest temperature/Temp on arrival (°C) | 35.0 (34.5:35.1), [33.2–35.4] |
| Lowest pH | 7.31 (7.25:7.33), [7.22–7.36] |
| Highest lactate (mmol/L) | 2.7 (1.8:3.0), [1.7–5.0] |
| **Vasoactive medications** | |
| Any vasoactive drug | 14 (78%) |
| Noradrenaline | No. of patients (%) | 12 (67%) |
| Total dose (mg) | 12.1 (4.7:31.0), [0.4–67.0] |
| Milrinone | No. of patients (%) | 5 (28%) |
| Total dose (mg) | 18.1 (12.2:29.6), [5.8–124.5] |
| Metaraminol | No. of patients (%) | 2 (11%) |
| Total dose (mg) | 0.5, 0.5 |
| Glyceryl trinitrate | No. of patients (%) | 1 (6%) |
| Total dose (mg) | 257.5 |
| Nitroprusside | No. of patients (%) | 1 (6%) |
| Total dose (mg) | 39.0 |
| **Opioids** | |
| Any opioid | 18 (100%) |
| Oral morphine equianalgesic dose (mg) | 103 (67:251), [8–580] |
| Morphine (IV) | No. of patients (%) | 8 (44%) |
| Total dose (mg) | 6.0 (3.3:11.3), [1–30] |
| Oxycodone (PO) | No. of patients (%) | 14 (78%) |
| Total dose (mg) | 33 (10:6:102), [5–360] |
| Tapentadol | No. of patients (%) | 1 (6%) |
| Total dose (mg) | 1,000 |
| Tramadol (IV/PO) | No. of patients (%) | 8 (44%) |
| Total dose (mg) | 300 (188:500), [100–500] |
| Fentanyl | No. of patients (%) | 3 (17%) |
| Total dose (mcg) | 120, 140, 180 |
| **Intravenous fluids** | |
| Any intravenous fluids | 18 (100%) |
| Crystalloids (CSL) | No. of patients (%) | 4 (22%) |
| Volume (L) | 1.0 (0.8:1.0), [0.3–1.2] |
| Colloids (4% albumin) | No. of patients (%) | 16 (89%) |
| Volume (L) | 1.4 (1.0:1.5), [0.5–2.0] |
| **Blood products** | |
| Red blood cells | No. of patients (%) | 14 (78%) |
| No. of units | 2.0 (1.3:3.0), [1.0–7.0] |
| Platelets | No. of patients (%) | 2 (11%) |
| No. of units | 1, 1 |
| Cryoprecipitate | No. of patients (%) | 1 (6%) |

(Continued)

TABLE 6 | Continued

| Variable | Open cardiac surgery (N = 18) |
|----------|-----------------------------|
| Fresh frozen plasma | No. of units | 3 |
| No. of patients (%) | 1 (6%) |
| Other interventions | |
| Tracheostomy | 0 (0%) |
| Reintubation | 0 (0%) |
| Non-invasive ventilation | 2 (11%) |
| High-flow nasal cannula | 3 (17%) |
| Antibiotics | 18 (100%) |
| Antiarrhythmics | 13 (72%) |
| Duretic | 13 (72%) |
| Vasopressin | 1 (6%) |
| Anticoagulation | 1 (6%) |
| Intra-aortic balloon pump | 0 (0%) |
| Renal replacement therapy | 0 (0%) |

Binary variables are presented as n (%) patients. Except where noted, numerical variables are presented as Mdn [interquartile range], range (minimum–maximum) and only include non-zero results. IV, intravenous; PO, per os (oral administration); CSL, compound sodium lactate.

Implications of Study Findings

Our findings suggest that with careful patient selection, comprehensive multidisciplinary care, and early involvement of geriatricians and perioperative physicians, reasonable outcomes can be achieved with acceptable morbidity and mortality in nonagenarians undergoing open cardiac surgery. Our findings also suggest that AKI, atrial fibrillation or flutter, and delirium are common in this vulnerable surgical cohort, and are targets for the implementation of specific preventative strategies. Furthermore, our study implies that the incidence of major complications was relatively low. Finally, the available data on 11-month survival supports the view that in selected nonagenarians, cardiac surgery poses an acceptable long-term mortality risk.

Strengths and Limitations

There are several strengths to the present study. We provide a detailed description of nonagenarians who have undergone open cardia surgery, including the granular data for key preoperative variables (including polypharmacy), detailed intraoperative variables and comprehensive postoperative outcome and complication data. The EuroSCORE-II database only contains 21 nonagenarian patients, therefore limiting its applicability to this cohort. Our results are applicable to a range of common cardiac surgeries. Data were drawn from multiple centres, using a standardised approach to define and grade complications. Finally, detailed follow-up data was available for all patients at 6 months postoperatively.

We acknowledge several limitations. First, given the retrospective study design, long-term follow-up was not available for eight patients. The small sample size together with the absence of long-term outcomes in some patients reduce the study's ability to provide a more detailed understanding of...
TABLE 7 | Complications, inpatient mortality, length of stay and follow-up of nonagenarians undergoing open cardiac surgery and transcatheter aortic valve replacement.

| Variable | Open cardiac surgery (N = 18) | Transcatheter aortic valve replacement (N = 27) |
|----------|-------------------------------|-----------------------------------------------|
| **Complications** |                               |                                               |
| Any complication | 17 (94%) | 15 (55.5%) |
| Number of complications | 2.0 (2.0:3.0), [1–4] | 1.0 (0.0:2.0), [0–5] |
| Return to theatre | 3 (17%) | 1 (3.7%) |
| Readmission | 3 (17%) | 1 (3.7%) |
| **Complications by type** |                               |                                               |
| Vascular access injury requiring intervention | 0 (0%) | 2 (7.4%) |
| Acute kidney injury | 13 (72%) | 5 (18.5%) |
| New atrial fibrillation and/or atrial flutter | 8 (44%) | 1 (3.7%) |
| Delirium | 7 (39%) | 1 (3.7%) |
| Pneumonia | 3 (17%) | 1 (3.7%) |
| Heart block and/or bradycardia requiring pacemaker | 2 (11%) | 1 (3.7%) |
| Pleural effusion | 1 (6%) | 0 (0%) |
| Gastrointestinal haemorrhage | 1 (6%) | 0 (0%) |
| Pneumothorax | 1 (6%) | 0 (0%) |
| Wound infection | 1 (6%) | 2 (7.4%) |
| Wound hematoma | 1 (6%) | 2 (7.4%) |
| Pressure injury | 1 (6%) | 0 (0%) |
| Urinary tract infection | 1 (6%) | 0 (0%) |
| **Complications by severity (Clavien–Dindo classification)** |                               |                                               |
| I | 14 (78%) | 3 (11.1%) |
| II | 10 (56%) | 10 (37.0%) |
| IIIa | 1 (6%) | 1 (3.7%) |
| IIb | 3 (17%) | 1 (3.7%) |
| IV | 0 (0%) | 0 (0%) |
| V | 0 (0%) | 0 (0%) |
| **Acute kidney injury by severity (KDIGO criteria)** |                               |                                               |
| Stage 1 | 5 (28%) | 3 (11.1%) |
| Stage 2 | 6 (33%) | 2 (7.4%) |
| Stage 3 | 2 (11%) | 0 (0%) |
| **Inpatient mortality** |                               |                                               |
| Intraoperative | 0 (0%) | 0 (0%) |
| In-hospital | 0 (0%) | 0 (0%) |
| **Length of stay** |                               |                                               |
| Postoperative (days) | 11.6 (9.8:17.6), [6.8–23.0] | 3.1 (2.9:4.9), [1.1–28.3] |
| **Discharge destination** |                               |                                               |
| Home | 1 (6%) | 25 (92.6%) |
| Inpatient rehabilitation facility | 17 (94%) | 2 (7.4%) |
| **Follow-up** |                               |                                               |
| Mortality at 6 months | 0 (0%) | 1 (3.7%) |
| Record of follow-up > 6 months after surgery | 10 (55%) | 27 (100%) |
| Time to recorded last follow-up (months) | 11.3 (6.0:26.4), [6.0–69.4] | 29.2 (18.2:39.5), [12–46] |

Binary variables are presented as n (%) patients. Numerical variables are presented as Mdn [interquartile range], range (minimum–maximum) and only include non-zero results. KDIGO, kidney disease: improving global outcomes.

long-term outcomes. Second, the nonagenarian patients in this study were all in the lower half of the age bracket, with a maximum age of 94. As such, the findings should be applied cautiously to those of more advanced age (i.e., > 95 years of age). Third, the preponderance of men in the study may limit the applicability of its findings to women. Fourth, in defining complications as a “deviation from the normal postoperative course,” physiological aberrations expected to some degree following cardiac surgery, such as vasoplegia, were not coded as complications. Instead, these aberrations were captured by the
duration and extent of the interventions used to manage them (e.g., vasopressor and ventilatory support). Similarly, certain conditions were only counted as a complication when managed with a specific intervention (e.g., pleural effusion requiring drainage). This inevitably reduced the number of complications recorded and partly predetermined their grading using the Clavien–Dindo system. Similarly, anemia in the postoperative period was also not counted as a complication given the high rate of anaemia preoperatively, with the transfusion of red blood cells instead used to provide an indication of the degree of blood loss and hemodilution.

Finally, because of the retrospective design, we acknowledge that functional and patient-centred outcomes, which are arguably more important than objective measures of morbidity and mortality in this nonagenarian cohort, could not be collected. Future studies may be enhanced by assessing functional outcome measures against metrics such as the World Health Organization’s Disability Assessment Schedule (53). Further studies with larger nonagenarian sample populations and prospective study designs may also facilitate a more robust multivariable analysis. Despite these limitations, our study provides a unique description of an uncommon presentation and serves as a contemporary hypothesis generating platform for future studies.

CONCLUSION

Nonagenarian patients undergoing cardiac surgery have an increased burden of comorbidity and often present for urgent or emergent surgery. Multidisciplinary patient selection and perioperative care can lead to acceptable outcomes in nonagenarians undergoing cardiac surgery via median sternotomy. Further prospective studies are needed to identify risk factors associated with adverse outcomes in nonagenarians, to explore potential prophylactic measures to reduce the risk of postoperative delirium, arrhythmia complications and acute kidney injury, and to assess quality of life and functional outcomes in this vulnerable population.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Austin Health Human Research Ethics Committee. Written informed consent for participation was not required for

---

**FIGURE 1** | Mortality in nonagenarians undergoing cardiac surgery. Excluded: single case reports, surgery on the thoracic aorta and reports where data could not be separated by age. Error bars represent mean ± standard error of the mean.
this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**
LW: study conception and design, data analysis and interpretation, and writing of manuscript. DW and DL: screening of literature, patient follow up, collection of data, data analysis, and writing of manuscript. JC, LM, and BC: screening of literature, collection of data, patient follow up, and writing of manuscript. AW and TN: collection of data, follow up of patients, and writing of manuscript. SS, GM, ZA, RB, and MY: data interpretation and writing of manuscript. All authors have read and approved the manuscript.

**REFERENCES**

1. Ogawa T, Schermann H, Kobayashi H, Fushimi K, Okawa A, Jinno T. Age and clinical outcomes after hip fracture surgery: do octogenarian, nonagenarian and centenarian classifications matter? Age Ageing. (2021) 50:1952–60. doi: 10.1093/ageing/abab137 (accessed January 17, 2022).

2. Revision of World Population Prospects. United Nations. Available online at: https://population.un.org/wpp/

3. Fowler AJ, Abbott TE, Frowle J, Pearse RM. Age of patients undergoing surgery. Br J Surg. (2019) 106:1012–8. doi: 10.1002/bjs.11148

4. Sağıv D, Migrov L, Lipschitz N, Dagan E, Gilkon E, Wolf M, et al. The admission patterns of octogenarians nonagenarians and centenarians to the department of otoearynology. Eur Arch Otorhinolaryngol. (2016) 273:4615–21. doi: 10.1007/s00405-016-4165-4

5. Farfía-Castro R, Roque-Castellano C, Marchena-Gómez J, Rodríguez-Pérez A. Five-year survival after surgery in nonagenarian patients. Geriatr Gerontol Int. (2017) 17:2389–95. doi: 10.1111/ggi.13081

6. Watters JM. Surgery in the elderly. Can J Surg. (2002) 45:104–8.

7. Irwin MG, Ip KY, Hui YM. Anaesthetic considerations in nonagenarians and centenarians. Curr Opin Anesthesiol. (2019) 32:776–82. doi: 10.1097/ACO.0000000000000793

8. Yap R, Oliva K, Wilkins S, McMurrick PJ. Colorectal cancer surgery in the very elderly: nonagenarians. Dis Colon Rectum. (2016) 59:501–7. doi: 10.1097/DCR.0000000000000578

9. Australian Department of Health. Modified Monash Model. (2019). Available online at: https://www.health.gov.au/health-topics/health-workforce/health-workforce-classifications/modified-monash-model (accessed April 14, 2022).

10. Australian Bureau of Statistics. Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA). Australia. (2011). Available online at: https://www.abs.gov.au/websitedbs/censushome.nsf/home/seifa (accessed April 14, 2022).

11. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of function and frailty in elderly people. CMAJ. (2005) 173:489–95. doi: 10.1503/cmaj.050051

12. Nashef SA, Drain AJ, Khan A, Ferguson J, Large SR, Nashef SA. Cardiac surgery in select nonagenarians: should we or shouldn’t we? Eur J Cardiothorac Surg. (2003) 240:205–13. doi: 10.1097/01.sla.0000133083.54934.ae

13. NHFA CSANZ Heart Failure Guidelines Working Group, Atherton J, Sindone A, De Pasquale CG, Driscoll A, et al. National heart foundation of Australia and cardiac society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018. Heart Lung Circ. (2018) 27:1123–208. doi: 10.1016/j.hlc.2018.06.1042

14. Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. (2013) 158:825–30. doi: 10.7326/0003-4819-158-11-201306040-00007

15. Murphy JF. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization (2011). Available online at: https://www.who.int/vmis/indicators/haemoglobin.pdf

16. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. (1994) 47:1245–51. doi: 10.1016/0895-4356(94)90129-5

17. Siros C, Domingues NS, Laroche ML, Zongo A, Lunghi C, Guinette L. Polypharmacy definitions for multimorbidity older adults need stronger foundations to guide research, clinical practice and public health. Pharmacy. (2019) 7:126. doi: 10.3390/pharmacy7030126

18. Thakar CV, Arrigain S, Worley S, Jared JP, Pagamini EP. A clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol. (2005) 16:62–8. doi: 10.1681/ASN.2004040331

19. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. (2004) 240:205–13. doi: 10.1097/01.sla.0000133083.54934.ae

20. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. (2007) 147:573–7. doi: 10.7326/0003-4819-147-8-200710160-00010

21. Easo J, Holzl PP, Horst M, Dikov V, Lütmathe J, Dapunt O. Cardiac surgery in nonagenarians: pushing the boundary one further decade. Arch Gerontol Geriatr. (2011) 53:229–32. doi: 10.1016/j.archger.2010.11.026

22. Assmann M, Minol JP, Mehdiyani A, Ahkhyari, P, Boeken, Lichtenberg A. Cardiac surgery in nonagenarians: not only feasible, but also reasonable? Interact Cardiovasc Thorac Surg. (2013) 17:540–3. doi: 10.1093/icvts/ivt125

23. Speziale G, Nasso G, Barattoni MC, Bonifazi R, Esposito G, Coppola R, et al. Operative and intermediate-term results of cardiac surgery in nonagenarians: a bridge toward routine practice. Circulation. (2010) 121:208–13. doi: 10.1161/CIRCULATIONAHA.108.807065

24. Guifoylde MR, Drain AJ, Khan A, Ferguson J, Large SR, Nashef SA. Cardiac surgery in nonagenarians: single-centre series and review. Gerontology. (2010) 56:5738–84. doi: 10.1159/000271602

25. Ullery BW, Peterson JC, Milla F, Wells MT, Briggs W, Girardini LN, et al. Cardiac surgery in select nonagenarians: should we or shouldn’t we? Ann Thorac Surg. (2008) 85:854–60. doi: 10.1016/j.athoracsur.2007.10.074

26. Bacchetta MD, Ko W, Girardini LN, Mack CA, Krieger KH, Isom OW, et al. Outcomes of cardiac surgery in nonagenarians: a 10-year experience. Ann Thorac Surg. (2003) 75:1215–20. doi: 10.1016/S0003-4975(02)04666-0

27. Blanche C, Matloff JM, Denton TA, Khan SS, DeRobertis MA, Nessim S, et al. Cardiac operations in patients 90 years of age and older. Ann Thorac Surg. (1997) 63:1685–90. doi: 10.1016/S0003-4975(97)00091-X

28. Zack CJ, Al-Qhtani F, Kawarsa A, Al-Hiji M, Amin AH, Alkhouli M. Comparative outcomes of surgical and transcatheter aortic valve replacement for aortic stenosis in nonagenarians. Am J Cardiol. (2017) 119:893–9. doi: 10.1016/j.amjcard.2016.11.045

29. Mack MC, Szelip M, Herbert MA, Akram S, Worley C, Kim RJ, et al. Outcomes of treatment of nonagenarians with severe aortic stenosis. Ann Thorac Surg. (2015) 100:74–80. doi: 10.1016/j.athoracsur.2015.02.045

30. Murashita T, Greason KL, Suri RM, Nkomo VT, Holmes DR, Rihal CS, et al. Aortic valve replacement for severe aortic valve stenosis in the nonagenarian patient. Ann Thorac Surg. (2014) 98:1593–7. doi: 10.1016/j.athoracsur.2014.06.015

31. Davis JP, LaPar DJ, Crosby IK, Kern JA, Lau CL, Kron IL, et al. Five-year survival after surgery in nonagenarian patients. J Card Surg. (2016) 31:94666-0
33. Caceres M, Cheng W, De Robertis M, Mirocha JM, Czer L, Esmaillian F, et al. Survival and quality of life for nonagenarians after cardiac surgery. Ann Thorac Surg. (2013) 95:1598–602. doi: 10.1016/j.athoracsur.2013.02.034

34. Hovanessian A, Moon MR, Rich MW. Cardiac surgery in nonagenarians. J Cardiovasc Surg. (2007) 48:757–60.

35. Levy Praschker BG, Leprince P, Bonnet N, Rama A, Bors V, Lievre L, et al. Cardiac surgery in nonagenarians: hospital mortality and long-term follow-up. Interact Cardiovasc Thorac Surg. (2006) 5:596–9. doi: 10.1510/icvts.2006.138255

36. Elgendy IY, Mahmoud AN, Elbadawi A, Elgendy AY, Omer MA, Megaly et al. Survival and quality of life for nonagenarians after cardiac valve surgery. J Am Coll Cardiol. (2016) 68:2012–20. doi: 10.1016/j.jacc.2016.05.018

37. Roberts WC, Ko JM, Matter GJ. Aortic valve replacement for aortic stenosis in nonagenarians. J Am J Cardiol. (2006) 98:1251–3. doi: 10.1016/j.amjcard.2006.05.061

38. Edwards MB, Taylor KM. Outcomes in nonagenarians after heart valve replacement operation. Ann Thorac Surg. (2003) 75:830–4. doi: 10.1016/S0003-4975(02)04558-7

39. Bridges CR, Edwards FH, Peterson ED, Coombs LP, Ferguson TB. Cardiac valve replacement operation. Ann Thorac Surg. (2003) 75:830–4. doi: 10.1016/S0003-4975(02)04558-7

40. Miller DJ, Samuels LE, Kaufman MS, Morris RJ, Thomas MP, Brockman SK. Coronary artery bypass surgery in nonagenarians. Angiology. (1999) 50:613–7. doi: 10.1177/000331999905000801

41. Samuels LE, Sharma S, Morris RJ, Kuretu ML, Grunewald KE, Strong MD. Coronary artery bypass grafting and/or aortic or mitral valve operation in patients > or = 90 years of age. Am J Cardiol. (1994) 74:960–2. doi: 10.1016/0002-9149(94)90599-1

42. Miller DJ, Samuels LE, Kaufman MS, Morris RJ, Thomas MP, Brockman SK. Coronary artery bypass surgery in nonagenarians. Angiology. (1999) 50:613–7. doi: 10.1177/000331999905000801

43. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. PARTNER Trial investigators. Transcatheter versus surgical aortic valve replacement in intermediate-risk patients. J Am Coll Cardiol. (2015) 65:2184–94. doi: 10.1016/j.jacc.2015.03.014

44. Leon MB, Smith CR, Mack MJ, Makkar TT, Svensson LG, Thourano VH, et al. Transcatheter or surgical aortic valve replacement in intermediate-risk patients. N Engl J Med. (2016) 374:1609–20. doi: 10.1056/NEJMoa1514616

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.